[go: up one dir, main page]

GT201000085A - COMPOSITIONS AND METHODS OF USE FOR ANTIBODIES AGAINST SCLEROSTINE - Google Patents

COMPOSITIONS AND METHODS OF USE FOR ANTIBODIES AGAINST SCLEROSTINE

Info

Publication number
GT201000085A
GT201000085A GT201000085A GT201000085A GT201000085A GT 201000085 A GT201000085 A GT 201000085A GT 201000085 A GT201000085 A GT 201000085A GT 201000085 A GT201000085 A GT 201000085A GT 201000085 A GT201000085 A GT 201000085A
Authority
GT
Guatemala
Prior art keywords
sclerostine
compositions
methods
antibodies against
antibodies
Prior art date
Application number
GT201000085A
Other languages
Spanish (es)
Inventor
Kneissel Michaela
Halleux Christine
Hu Shou-Lh
Diefenbach-Streiber Beate
Prassler Josef
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40219404&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201000085(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of GT201000085A publication Critical patent/GT201000085A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/108—Osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)

Abstract

LA PRESENTE INVENCIÓN SE RELACIONA CON ANTICUERPOS CONTRA LA ESCLEROSTINA Y COMPOSICIONES Y MÉTODOS DE USO PARA ESTOS ANTICUERPOS PARA TRATAR ENFERMEDAD RELACIONADA CON ANORMALIDADES ÓSEAS TALES COMO LA OSTEOPOROSIS.THIS INVENTION IS RELATED TO ANTIBODIES AGAINST SCLEROSTINE AND COMPOSITIONS AND METHODS OF USE FOR THESE ANTIBODIES TO TREAT DISEASE RELATED TO SUCH BONE ABNORMALITIES SUCH AS OSTEOPOROSIS.

GT201000085A 2007-10-12 2010-04-09 COMPOSITIONS AND METHODS OF USE FOR ANTIBODIES AGAINST SCLEROSTINE GT201000085A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07118414 2007-10-12
EP08151911 2008-02-25
EP08161342 2008-07-29

Publications (1)

Publication Number Publication Date
GT201000085A true GT201000085A (en) 2014-03-14

Family

ID=40219404

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201000085A GT201000085A (en) 2007-10-12 2010-04-09 COMPOSITIONS AND METHODS OF USE FOR ANTIBODIES AGAINST SCLEROSTINE

Country Status (34)

Country Link
US (3) US7879322B2 (en)
EP (2) EP2586796B1 (en)
JP (3) JP2011502470A (en)
KR (2) KR20130029452A (en)
CN (1) CN101821291B (en)
AR (1) AR068767A1 (en)
AU (1) AU2008309514B2 (en)
CA (1) CA2702005C (en)
CL (1) CL2008003004A1 (en)
CO (1) CO6270368A2 (en)
CR (1) CR11313A (en)
CU (1) CU23869B1 (en)
CY (2) CY1114872T1 (en)
DK (2) DK2586796T3 (en)
EA (1) EA018756B1 (en)
ES (2) ES2614328T3 (en)
GT (1) GT201000085A (en)
HN (1) HN2010000674A (en)
HR (2) HRP20140161T1 (en)
HU (1) HUE031995T2 (en)
IL (1) IL204510A (en)
LT (1) LT2586796T (en)
MA (1) MA31760B1 (en)
MX (1) MX2010003915A (en)
MY (1) MY152282A (en)
NZ (1) NZ584158A (en)
PE (1) PE20091221A1 (en)
PL (2) PL2586796T3 (en)
PT (2) PT2586796T (en)
SI (2) SI2586796T1 (en)
TN (1) TN2010000140A1 (en)
TW (1) TWI489993B (en)
WO (1) WO2009047356A1 (en)
ZA (1) ZA201001789B (en)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2639020T3 (en) 1998-11-27 2017-10-25 Ucb Pharma S.A. Compositions and methods to increase bone substance mineralization
US20040009535A1 (en) * 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
WO2005014650A2 (en) 2003-06-16 2005-02-17 Celltech R & D, Inc. Antibodies specific for sclerostin and methods for increasing bone mineralization
US8461155B2 (en) * 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US7723477B2 (en) * 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
EP2511298B1 (en) 2005-10-31 2019-01-16 Oncomed Pharmaceuticals, Inc. Compositions and Methods for Treating Cancer based on human FZD receptors
ES2666650T3 (en) * 2006-12-29 2018-05-07 OstéoQC Inc. Methods to alter bone growth by administration of antagonist or agonist of support or wise
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
EP2222846B1 (en) * 2007-08-10 2017-05-03 Protelix, Inc. Universal fibronectin type iii binding-domain libraries
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
CL2008002775A1 (en) 2007-09-17 2008-11-07 Amgen Inc Use of a sclerostin binding agent to inhibit bone resorption.
AR068767A1 (en) * 2007-10-12 2009-12-02 Novartis Ag ANTIBODIES AGAINST SCLEROSTIN, COMPOSITIONS AND METHODS OF USE OF THESE ANTIBODIES TO TREAT A PATHOLOGICAL DISORDER MEDIATIONED BY SCLEROSTIN
WO2009064944A2 (en) 2007-11-16 2009-05-22 Nuvelo, Inc. Antibodies to lrp6
UA121453C2 (en) 2008-04-11 2020-06-10 Чугей Сейяку Кабусікі Кайся METHOD OF PREPARATION OF PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY
BRPI0919473A2 (en) * 2008-09-26 2017-08-29 Oncomed Pharm Inc FRIZZLED BINDING AGENTS AND THEIR USES
AR075715A1 (en) * 2009-03-05 2011-04-20 Novartis Ag FORMULATION OF LIOFILIZED ANTIBODY
WO2010115932A1 (en) 2009-04-08 2010-10-14 Novartis Ag Combination for the treatment of bone loss
WO2011037791A1 (en) * 2009-09-25 2011-03-31 Merck Sharp & Dohme Corp. Antagonists of pcsk9
TWI535445B (en) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Wnt antagonists and methods of treatment and screening
NZ602700A (en) 2010-04-01 2014-10-31 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
PH12012501991A1 (en) 2010-04-07 2017-07-26 Abbvie Inc Tnf-alpha binding proteins
MX2012012050A (en) * 2010-04-16 2012-11-22 Novartis Ag Methods and compositions for improving implant osseointegration.
CA2798390A1 (en) 2010-05-06 2011-11-10 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
EP2566892B1 (en) 2010-05-06 2017-12-20 Novartis AG Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies
SMT202000095T1 (en) 2010-05-14 2020-03-13 Amgen Inc High concentration anti-sclerostin antibody formulations
US9493541B2 (en) 2010-06-07 2016-11-15 Joshua Rabbani Antibodies specific for sulfated sclerostin
US9617323B2 (en) 2010-06-07 2017-04-11 Joshua Rabbani Sulfonated sclerostin, antibodies, epitopes and methods for identification and use therefor
US9403882B2 (en) 2010-06-07 2016-08-02 Joshua Rabbani Sulfation of Wnt pathway proteins
US11167011B2 (en) 2010-06-07 2021-11-09 Enzo Biochem, Inc. Methods for treating bone loss using sclerostin peptides
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery
AR083740A1 (en) 2010-10-27 2013-03-20 Amgen Inc DKK1 ANTIBODIES (DICKKOPF-1) AND METHODS OF USE
TWI618543B (en) 2010-11-05 2018-03-21 諾華公司 Use of IL-17 antibody for the preparation of a medicament for treating ankylosing spondylitis
KR102385507B1 (en) 2010-11-30 2022-04-12 추가이 세이야쿠 가부시키가이샤 Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
JP2014509588A (en) * 2011-03-01 2014-04-21 アムジエン・インコーポレーテツド Bispecific binding agent
WO2012135035A1 (en) 2011-03-25 2012-10-04 Amgen Inc. Anti - sclerostin antibody crystals and formulations thereof
SMT201800489T1 (en) 2011-04-19 2018-11-09 Amgen Inc Method for treating osteoporosis
WO2012149246A1 (en) 2011-04-29 2012-11-01 Novartis Ag Methods of treating squamous cell carcinoma related applications
MX355816B (en) * 2011-08-04 2018-05-02 Amgen Inc Method for treating bone gap defects.
US10813630B2 (en) 2011-08-09 2020-10-27 Corquest Medical, Inc. Closure system for atrial wall
US10314594B2 (en) 2012-12-14 2019-06-11 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10307167B2 (en) 2012-12-14 2019-06-04 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
TW201323440A (en) * 2011-10-24 2013-06-16 Abbvie Inc Immunobinders directed against sclerostin
TW201326207A (en) 2011-10-24 2013-07-01 Abbvie Inc anti-TNF immunoconjugate
UY34410A (en) 2011-10-24 2013-05-31 Abbvie Inc BISPECIFIC IMMUNOLIGANTS DIRECTED AGAINST TNF
EP3252075A1 (en) 2011-11-04 2017-12-06 Novartis AG Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs
EA202091676A1 (en) 2011-12-28 2021-01-29 Эмджен Инк. METHOD FOR TREATMENT OF BONE MASS LOSS OF ALVEOLAR PROCESSING BY APPLICATION OF ANTIBODIES TO SCLEROSTIN
AU2013285488B2 (en) * 2012-07-05 2018-03-22 Ucb Pharma S.A. Treatment for bone diseases
JP2015536933A (en) 2012-10-23 2015-12-24 オンコメッド ファーマシューティカルズ インコーポレイテッド Methods of treating neuroendocrine tumors using Wnt pathway binding agents
UY35148A (en) 2012-11-21 2014-05-30 Amgen Inc HETERODIMERIC IMMUNOGLOBULINS
US20140142689A1 (en) 2012-11-21 2014-05-22 Didier De Canniere Device and method of treating heart valve malfunction
JP2016501875A (en) 2012-11-29 2016-01-21 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅＬＬＣ Humanized monoclonal antibody against activated protein C and use thereof
HK1212896A1 (en) * 2012-11-29 2016-06-24 Bayer Healthcare Llc Monoclonal antibodies against activated protein c (apc)
WO2014118705A1 (en) 2013-01-31 2014-08-07 Novartis Ag Methods of treating chronic kidney disease-mineral and bone disorder using sclerostin antagonists
AU2014212081A1 (en) 2013-02-04 2015-08-13 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
MX369360B (en) * 2013-03-20 2019-11-06 Baylor College Medicine Methods for treating osteogenesis imperfecta.
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
US9566443B2 (en) 2013-11-26 2017-02-14 Corquest Medical, Inc. System for treating heart valve malfunction including mitral regurgitation
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
US9763911B2 (en) 2013-12-12 2017-09-19 Mayo Foundation For Medical Education And Research Prostacyclin compositions for regulation of fracture repair and bone formation
US10842626B2 (en) 2014-12-09 2020-11-24 Didier De Canniere Intracardiac device to correct mitral regurgitation
MA41142A (en) * 2014-12-12 2017-10-17 Amgen Inc ANTI-SCLEROSTINE ANTIBODIES AND THE USE OF THEM TO TREAT BONE CONDITIONS AS PART OF THE TREATMENT PROTOCOL
AR103173A1 (en) 2014-12-22 2017-04-19 Novarits Ag PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF ANTIBODIES IL-17
CA2978976C (en) * 2015-03-13 2024-05-14 Jiangsu Hengrui Medicine Co., Ltd. Anti-sclerostin antibody, antigen binding fragment and medical use thereof
US11077187B2 (en) 2015-11-17 2021-08-03 Oklahoma Medical Research Foundation Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
EP3496744A1 (en) 2016-08-08 2019-06-19 Amgen Inc. Method of improving connective tissue attachment using anti-sclerostin antibodies
US10961305B2 (en) 2016-12-21 2021-03-30 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
KR102706743B1 (en) * 2016-12-21 2024-09-19 세파론 엘엘씨 Antibodies that specifically bind to human il-15 and uses thereof
FI3478719T6 (en) 2016-12-21 2025-01-20 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
US11608374B2 (en) 2017-01-30 2023-03-21 Chugai Seiyaku Kabushiki Kaisha Anti-sclerostin antibodies and methods of use
CN108866002A (en) * 2017-05-12 2018-11-23 上海复旦张江生物医药股份有限公司 For SOST albumen or the cell strain of antibody screening and its preparation method and application
MX2020000582A (en) 2017-07-27 2020-09-10 Jiangsu Hengrui Medicine Co Sost antibody pharmaceutical composition and uses thereof.
CN107817350B (en) * 2017-10-26 2019-09-06 成都医学院第一附属医院 A lung cancer screening kit
US11883445B2 (en) 2018-03-14 2024-01-30 Emory University Lactococcus bacteria and uses thereof
CA3093457A1 (en) 2018-03-30 2019-10-03 Amgen Inc. C-terminal antibody variants
GB201810746D0 (en) 2018-06-29 2018-08-15 Mereo Biopharma 3 Ltd Use of sclerostin antagonist
IL280642B2 (en) 2018-08-10 2025-09-01 Amgen Inc Method of preparing an antibody pharmaceutical formulation
CN118307669A (en) * 2019-07-12 2024-07-09 国立大学法人京都大学 Neutralizing antibodies targeting USAG-1 for tooth regeneration therapy
WO2021030179A1 (en) 2019-08-12 2021-02-18 Amgen Inc. Anti-sclerostin antibody formulations
TR201920272A1 (en) * 2019-12-15 2021-06-21 Uludamar Altay A THERAPEUTIC COMPOSITION FOR INCREASING OSSEOINTEGRATION WITH DENTAL IMPLANTS, GRAFT MATERIALS AND PRF AND ITS LOCAL USE METHODS
CN112070678B (en) * 2020-08-10 2023-04-11 华东交通大学 Batch Western blot membrane strip inclination correction and segmentation method and system
KR102472582B1 (en) * 2020-08-20 2022-11-30 한림대학교 산학협력단 Diagnosis and treatment of synovitis and osteolysis caused by artificial joint wear
CN118146382A (en) * 2020-09-28 2024-06-07 安济盛生物医药有限公司 Anti-sclerostin constructs and uses thereof
CN113354724A (en) * 2021-04-28 2021-09-07 蒋青 Sclerostin and application thereof in preparation of related products for treating or preventing Alzheimer's disease
WO2025019728A1 (en) 2023-07-19 2025-01-23 Amgen Inc. Methods of buffer preparation for a therapeutic protein formulation

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US6455275B1 (en) 1980-02-25 2002-09-24 The Trustees Of Columbia University In The City Of New York DNA construct for producing proteinaceous materials in eucaryotic cells
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (en) 1985-06-26 1992-08-01 Liposome Co Inc LIPOSOMAS COUPLING METHOD.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
DE3853515T3 (en) 1987-05-21 2005-08-25 Micromet Ag MULTIFUNCTIONAL PROTEINS WITH SPECIFIC OBJECTIVES.
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
SE509359C2 (en) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Use of stabilized protein or peptide conjugates for the preparation of a drug
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DK0463151T3 (en) 1990-01-12 1996-07-01 Cell Genesys Inc Generation of xenogenic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
JP2938569B2 (en) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド Method for producing xenogeneic immunoglobulin and transgenic mouse
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JPH059615A (en) 1991-07-01 1993-01-19 Sumitomo Metal Mining Co Ltd Recovery method of sponge Cd
DE69233782D1 (en) 1991-12-02 2010-05-20 Medical Res Council Preparation of Autoantibodies on Phage Surfaces Starting from Antibody Segment Libraries
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
ATE420178T1 (en) 1992-08-21 2009-01-15 Univ Bruxelles IMMUNOGLOBULINS WITHOUT LIGHT CHAIN
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
SE9400088D0 (en) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
ATE394492T1 (en) 1996-10-28 2008-05-15 Univ Lausanne METHOD FOR OLIGOMERIZATION OF PEPTIDES
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
ATE319745T1 (en) 1997-05-21 2006-03-15 Biovation Ltd METHOD FOR PRODUCING NON-IMMUNOGENIC PROTEINS
ES2231991T3 (en) 1997-06-11 2005-05-16 Borean Pharma A/S TRIMERIZATION MODULE.
DE19742706B4 (en) 1997-09-26 2013-07-25 Pieris Proteolab Ag lipocalin muteins
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
PT1071700E (en) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
AU776049B2 (en) 1998-10-09 2004-08-26 United Kingdom Research And Innovation Method for generating diversity
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
ES2639020T3 (en) 1998-11-27 2017-10-25 Ucb Pharma S.A. Compositions and methods to increase bone substance mineralization
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
EP1141024B1 (en) 1999-01-15 2018-08-08 Genentech, Inc. POLYPEPTIDE COMPRISING A VARIANT HUMAN IgG1 Fc REGION
ES2601882T5 (en) 1999-04-09 2021-06-07 Kyowa Kirin Co Ltd Procedure to monitor the activity of an immunofunctional molecule
DE19932688B4 (en) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design of beta-sheet proteins of gamma-II-crystalline antibody-like
DE60041119D1 (en) 1999-07-20 2009-01-29 Morphosys Ag METHOD FOR THE PRESENTATION OF (POLY) PEPTIDES / PROTEINS ON BACTERIOPHAGE PARTICLES VIA DISULPIDE BINDINGS
ATE354655T1 (en) 1999-08-24 2007-03-15 Medarex Inc HUMAN ANTIBODIES TO CTLA-4 AND THEIR USES
US7943129B2 (en) 2000-05-26 2011-05-17 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
KR20060088905A (en) 2000-06-16 2006-08-07 휴먼 게놈 사이언시즈, 인코포레이티드 Antibodies that immunospecifically bind to LYXs
EP1916303B1 (en) 2000-11-30 2013-02-27 Medarex, Inc. Nucleic acids encoding rearranged human immunoglobulin sequences from transgenic transchromosomal mice
JP4406206B2 (en) * 2001-04-24 2010-01-27 バイエル コーポレーション Human TIMP-1 antibody
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
EP1421203A4 (en) 2001-05-17 2005-06-01 Diversa Corp Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
CA2467521A1 (en) 2001-11-16 2003-07-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
AU2003276430A1 (en) 2002-06-14 2003-12-31 Stowers Institute For Medical Research Wise/sost nucleic acid sequences and amino acid sequences
US20040065598A1 (en) 2002-06-17 2004-04-08 Ross David Justin Address disambiguation for mail-piece routing
FR2840910B1 (en) 2002-06-17 2004-08-27 Rhodia Chimie Sa SILICONE COMPOSITION FOR THE PRODUCTION OF AN ASSEMBLY COMPRISING SEVERAL SILICONE ELEMENTS CROSSLINKED BY POLYADDITION TIGHTLY ADHERING TO OTHERS
CA2503697A1 (en) 2002-10-29 2004-05-13 Borean Pharma A/S Trimeric binding proteins for trimeric cytokines
DE10324447A1 (en) 2003-05-28 2004-12-30 Scil Proteins Gmbh Generation of artificial binding proteins based on ubiquitin
WO2005014650A2 (en) 2003-06-16 2005-02-17 Celltech R & D, Inc. Antibodies specific for sclerostin and methods for increasing bone mineralization
US8461155B2 (en) 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
JP4782700B2 (en) 2004-01-20 2011-09-28 カロバイオス ファーマシューティカルズ インコーポレイティッド Transfer of antibody specificity using minimally required binding determinants
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
WO2006102671A1 (en) 2005-03-24 2006-09-28 E. I. Du Pont De Nemours And Company Process to prepare stable trifluorostyrene containing compounds grafted to base polymers using a solvent/water mixture
WO2006102670A1 (en) 2005-03-24 2006-09-28 E. I. Du Pont De Nemours And Company Process to prepare stable trifluorostyrene containing compounds grafted to base polymers
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) * 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
DE102006002221A1 (en) 2005-11-11 2007-05-24 Micronas Gmbh Integrated electronic circuit
WO2007055341A1 (en) * 2005-11-11 2007-05-18 Biomarker Science Co., Ltd. Method for differential prediction/diagnosis of diabetes and kit for prediction/diagnosis of diabetes
DOP2006000277A (en) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp ANTI MN ANTIBODIES AND METHODS FOR USE
AR060017A1 (en) 2006-01-13 2008-05-21 Novartis Ag COMPOSITIONS AND METHODS OF USE FOR DICKKOPF -1 ANTIBODIES
EP2094731A2 (en) 2006-11-10 2009-09-02 UCB Pharma S.A. Anti human sclerostin antibodies
EP2423226A3 (en) 2006-11-10 2012-05-30 Amgen Inc. Antibody-based diagnostics and therapeutics
ES2666650T3 (en) 2006-12-29 2018-05-07 OstéoQC Inc. Methods to alter bone growth by administration of antagonist or agonist of support or wise
EA018204B1 (en) 2007-03-20 2013-06-28 Эли Лилли Энд Компани Anti-sclerostin antibodies
CL2008002775A1 (en) 2007-09-17 2008-11-07 Amgen Inc Use of a sclerostin binding agent to inhibit bone resorption.
AR068767A1 (en) * 2007-10-12 2009-12-02 Novartis Ag ANTIBODIES AGAINST SCLEROSTIN, COMPOSITIONS AND METHODS OF USE OF THESE ANTIBODIES TO TREAT A PATHOLOGICAL DISORDER MEDIATIONED BY SCLEROSTIN
WO2009079471A1 (en) 2007-12-14 2009-06-25 Amgen Inc. Method for treating bone fracture with anti-sclerostin antibodies

Also Published As

Publication number Publication date
HRP20140161T1 (en) 2014-03-28
PE20091221A1 (en) 2009-09-11
EP2586796B1 (en) 2016-12-07
CU23869B1 (en) 2013-03-27
HK1143173A1 (en) 2010-12-24
PL2203478T3 (en) 2014-05-30
JP5913181B2 (en) 2016-04-27
IL204510A (en) 2013-01-31
JP2016121170A (en) 2016-07-07
ES2448542T3 (en) 2014-03-14
CR11313A (en) 2010-05-06
WO2009047356A1 (en) 2009-04-16
MY152282A (en) 2014-09-15
CL2008003004A1 (en) 2009-06-26
PT2586796T (en) 2017-03-15
US20090130113A1 (en) 2009-05-21
HRP20170347T1 (en) 2017-08-11
MX2010003915A (en) 2010-04-30
CN101821291A (en) 2010-09-01
US20120276591A1 (en) 2012-11-01
KR20100074271A (en) 2010-07-01
AR068767A1 (en) 2009-12-02
CY1118691T1 (en) 2017-07-12
ES2614328T3 (en) 2017-05-30
CY1114872T1 (en) 2016-12-14
HN2010000674A (en) 2013-02-04
ZA201001789B (en) 2011-12-28
JP6401196B2 (en) 2018-10-03
KR101268675B1 (en) 2013-06-25
PL2586796T3 (en) 2017-05-31
DK2203478T3 (en) 2014-02-10
DK2586796T3 (en) 2017-02-13
HUE031995T2 (en) 2017-08-28
CA2702005C (en) 2016-06-14
LT2586796T (en) 2017-02-27
MA31760B1 (en) 2010-10-01
AU2008309514B2 (en) 2011-06-23
EP2586796A1 (en) 2013-05-01
SI2203478T1 (en) 2014-03-31
CN101821291B (en) 2013-04-10
CA2702005A1 (en) 2009-04-16
PT2203478E (en) 2014-02-25
EP2203478B1 (en) 2013-11-20
TWI489993B (en) 2015-07-01
KR20130029452A (en) 2013-03-22
CO6270368A2 (en) 2011-04-20
US8486661B2 (en) 2013-07-16
BRPI0817879A2 (en) 2014-06-17
EA201000559A1 (en) 2010-10-29
JP2013153757A (en) 2013-08-15
SI2586796T1 (en) 2017-04-26
AU2008309514A1 (en) 2009-04-16
TN2010000140A1 (en) 2011-09-26
EA018756B1 (en) 2013-10-30
TW200922621A (en) 2009-06-01
NZ584158A (en) 2011-10-28
US8246953B2 (en) 2012-08-21
JP2011502470A (en) 2011-01-27
EP2203478A1 (en) 2010-07-07
US20110052592A1 (en) 2011-03-03
US7879322B2 (en) 2011-02-01
CU20100059A7 (en) 2012-06-29

Similar Documents

Publication Publication Date Title
GT201000085A (en) COMPOSITIONS AND METHODS OF USE FOR ANTIBODIES AGAINST SCLEROSTINE
MX337575B (en) SULFONE COMPOUNDS AND METHODS FOR THE MANUFACTURE AND USE OF THESE.
EA201170161A1 (en) 1,2,5-OXADIAZYLES AS INDLAMIN-2,3-DIOXYENASE INHIBITORS
EA201491766A1 (en) CONNECTIONS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY
UY33735A (en) ANTIVIRAL COMPOUNDS
EA201491412A1 (en) CONNECTIONS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY
EA201101686A1 (en) NEW COMPOSITIONS FOR THE TREATMENT OF CMT AND RELATED DISORDERS
GT201400057A (en) 3-PIRMIDIN-4-IL-OXAZOLIDIN-2-ONAS AS INHIBITORS OF THE MUTANT HDI
EA200900203A1 (en) ELECTORAL MODULATORS OF ANDROGENS RECEPTOR, THEIR ANALOGUES, DERIVATIVES AND APPLICATIONS
MX2018009945A (en) Novel compositions and methods for the treatment of immune related diseases.
EA201792465A1 (en) CONNECTIONS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY
CO6511271A2 (en) IMIDAZOPIRIDINIL-AMINOPIRIDINE SUBSTITUTED COMPOUNDS
GT201200258A (en) COMPOSITIONS OF ANTI-FACTOR ANTI-FACTOR OF NERVOUS GROWTH (NGF)
MX2011011352A (en) Compositions and methods for increasing muscle growth.
EA201200794A1 (en) TRIAZOLOPRYRIDINS
IN2013CN01340A (en)
EA201270575A1 (en) CONNECTIONS
HN2010001761A (en) DERIVATIVES OF AZETIDINE AND CYCLLOBUTANE AS JAK INHIBITORS
EA201190259A1 (en) ANTI-VIRUS COMPOUNDS
EA201171435A1 (en) SOLID PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR PRODUCTION
UY33238A (en) "Compounds as bradykinin-b1 antagonists"
PH12012501680A1 (en) Compositions and methods for the diagnosis and treatment of tumor
BR102014006335B8 (en) Method for producing an isolated population of immature dental pulp stem cells (idpscs) and use
MX357166B (en) Antibodies to notum pectinacetylesterase.
PH12012501963A1 (en) Compositions and methods for the diagnosis and treatment of tumor